Ocular Angiogenesis Group, Department of Ophthalmology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands; Department of Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188446. doi: 10.1016/j.bbcan.2020.188446. Epub 2020 Oct 12.
Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a major focus of fundamental and clinical research. However, survival benefits of current anti-angiogenic agents, such as bevacizumab, in patients with gynecological cancer, are modest. Therefore, a better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies, either or not in combination with other therapeutic approaches. We describe the molecular aspects of (tumor) blood vessel formation and the tumor microenvironment and provide an extensive clinical overview of current anti-angiogenic therapies for gynecological cancers. We discuss the different phenotypes of angiogenic endothelial cells as potential therapeutic targets, strategies aimed at intervention in their metabolism, and approaches targeting their (inflammatory) tumor microenvironment.
血管生成是癌症（包括妇科癌症）中原发性肿瘤和继发性转移生长所必需的。在妇科癌症中开发抗血管生成治疗并提高其疗效一直是基础和临床研究的重点。然而，目前抗血管生成药物（如贝伐珠单抗）在妇科癌症患者中的生存获益有限。因此，迫切需要更好地了解妇科癌症中的血管生成和肿瘤微环境，以开发更有效的抗血管生成治疗方法，无论是单独使用还是与其他治疗方法联合使用。我们描述了（肿瘤）血管形成的分子方面和肿瘤微环境，并广泛概述了目前用于妇科癌症的抗血管生成治疗方法。我们讨论了血管生成内皮细胞的不同表型作为潜在的治疗靶点、针对其代谢的干预策略以及针对其（炎症）肿瘤微环境的方法。
